SLC50A1 inhibits the doxorubicin sensitivity in hepatocellular carcinoma cells through regulating the tumor glycolysis

Ganggang Wang, Wenzhi Jin, Lianmei Zhang, Meiyuan Dong, Xin Zhang, Zhijie Zhou, Xiaoliang Wang · 2024

Read SLC50A1 inhibits the doxorubicin sensitivity in hepatocellular carcinoma cells through regulating the tumor glycolysis by Ganggang Wang, Wenzhi Jin, Lianmei Zhang, Meiyuan Dong, Xin Zhang, Zhijie Zhou, Xiaoliang Wang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11655560.txt.

Description

Ganggang Wang and co-authors study a sugar transport gene that helps liver cancer resist chemotherapy, in this 2024 paper. The gene, SLC50A1, moves glucose across cell membranes. It ran high in liver tumors and tracked with poor patient outlook. The team asked how it drives tumor growth and drug resistance, testing cells and animals.

Raising the gene sped tumor cell growth, boosted sugar burning, and cut cell death. It also blunted the effect of the drug doxorubicin and of a sugar-blocking compound. A second player, an RNA-marking enzyme, tags the gene's message and stabilizes it, forming a two-step axis. The authors name that axis a fresh treatment target for liver cancer, aiming to restore drug sensitivity.

Catalog record

CREATORGanggang Wang, Wenzhi Jin, Lianmei Zhang, Meiyuan Dong, Xin Zhang, Zhijie Zhou, Xiaoliang Wang
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11655560

Browse the full library · About the Tower of Babel